US WorldMeds to Present Final SPEARHEAD-1 Results for TECELRA® in Late-Breaking Oral Presentation at CTOS 2026
Results from all cohorts of the registrational trial selected for the session “Late Breaking Abstracts and Updates – Can They Change Practice?”
LOUISVILLE, Ky., Nov. 17, 2026 /PRNewswire/ — USWM CT, LLC (US WorldMeds) today announced that final results from all cohorts of the Phase 2 SPEARHEAD-1 trial of TECELRA® (afamitresgene autoleucel) in advanced synovial sarcoma will be featured in a late-breaking oral presentation at the 2026 Connective Tissue Oncology Society (CTOS) Annual Meeting, taking place November 18–21 in Seoul, South Korea.
The presentation will report safety results and independently reviewed efficacy outcomes across SPEARHEAD-1 Cohorts 1, 2 and 3 — the most comprehensive dataset to date for the first FDA-approved engineered T-cell therapy for a solid tumor.
“Selection for a late-breaking oral session reflects the sarcoma community’s growing attention to cellular therapy,” said Kristen Gullo, Senior Vice President, US WorldMeds. “We look forward to sharing the complete SPEARHEAD-1 dataset with the clinicians who treat patients facing this rare and aggressive cancer.”
US WorldMeds will also present four additional posters at CTOS 2026 covering factors associated with TECELRA clinical outcomes, comparative effectiveness of TECELRA and other available therapies, engineered T-cell therapies in pediatric synovial sarcoma, and first-line synovial sarcoma treatment with letetresgene autoleucel.
Presentation Details
- Title: The SPEARHEAD-1 Trial of Afamitresgene Autoleucel (Afami-cel) in Advanced Synovial Sarcoma: Results of All Cohorts
- Abstract ID: 2462069
- Session: Session 8: Late Breaking Abstracts and Updates – Can They Change Practice?
- Date/Time: Friday, November 20, 2026, 11:30 a.m. – 1:00 p.m. [KST]
- Author: Sandra P. D’Angelo, MD
What is TECELRA?
TECELRA is a melanoma-associated antigen A4 (MAGE-A4)-directed genetically modified autologous T cell immunotherapy indicated for the treatment of adults and pediatric patients 12 years of age and older with unresectable or metastatic synovial sarcoma who have received prior chemotherapy, are HLA-A*02:01P, -A*02:02P, -A*02:03P, or -A*02:06P positive and whose tumor expresses the MAGE-A4 antigen as determined by FDA-approved or cleared companion diagnostic devices.
IMPORTANT SAFETY INFORMATION
Important Warning: You will likely be in a hospital before and after getting TECELRA. TECELRA may cause side effects that can be severe or life-threatening. Call your healthcare provider or get emergency help right away if you get any of the following: fever (100.4°F/38°C or higher); chills/shivering; difficulty breathing; fast or irregular heartbeat; low blood pressure; fatigue; severe nausea, vomiting, or diarrhea; severe headache; or new skin rash. Tell all your healthcare providers that you were treated with TECELRA.
After getting TECELRA, you will be monitored daily at the healthcare facility for at least 7 days after the infusion. You should plan to stay close to a healthcare facility for at least 2 weeks. Do not drive, operate heavy machinery, or do other activities that could be dangerous for at least 2 weeks after you get TECELRA. Your healthcare provider will do blood tests to follow your progress. It is important that you have your blood tested. If you miss a scheduled appointment for your collection of blood, call your healthcare provider as soon as possible to reschedule.
Before you receive TECELRA, tell your healthcare provider about all the medicines and supplements you take and your medical conditions, including: seizure, stroke, confusion, or memory loss; heart, liver, or kidney problems; low blood pressure; lung or breathing problems; recent or active infection; past infections that can be reactivated following treatment with TECELRA; low blood counts; pregnancy, you think you may be pregnant, or plan to become pregnant; breastfeeding; or taking a blood thinner.
The most common side effects of TECELRA include nausea, fatigue, infection, fever (100.4°F/38°C or higher), constipation, vomiting, headache, diarrhea, fast heart rate, cough, increased aspartate aminotransferase, increased alanine aminotransferase, decreased lymphocyte count, decreased white blood cell count, decreased neutrophil count, decreased red blood cell count, and decreased platelet count.
You are encouraged to report side effects to the FDA at (800) FDA-1088 or www.fda.gov/medwatch or to US WorldMeds at 1-855-246-9232.
Please see full Prescribing Information, including Boxed Warning and Medication Guide.
What is letetresgene autoleucel?
Letetresgene autoleucel (lete-cel) is an investigational therapy and has not been approved by the U.S. Food and Drug Administration (FDA) or any other regulatory authority for any use. Its safety and efficacy have not been established, and there is no guarantee that lete-cel will be approved or commercially available in any country. Data on lete-cel presented at CTOS 2026 are not intended to promote or to suggest safety or effectiveness for any use of lete-cel. TECELRA® is the only product referenced in this press release that is FDA-approved.
About US WorldMeds
US WorldMeds is a U.S.-based pharmaceutical company focused on rare disease and specialty treatments. Our portfolio includes approved therapies for rare diseases, including IWILFIN®, REVONTO®, and TECELRA®.
Forward-Looking Statements
This press release contains forward-looking statements, including statements regarding the potential benefits of TECELRA, patient identification, and future research. Actual results may differ materially due to risks and uncertainties inherent in clinical development, regulatory review, and commercialization. US WorldMeds undertakes no obligation to update forward-looking statements except as required by law.
Media Contact
Stephen Camiolo
Head of Cell Therapy Commercialization
USWM CT, LLC
Phone: 1-833-935-6676
Email: 427244@email4pr.com
View original content:https://www.prnewswire.com/news-releases/us-worldmeds-to-present-final-spearhead-1-results-for-tecelra-in-late-breaking-oral-presentation-at-ctos-2026-302942307.html
SOURCE US WorldMeds
